Back to results
US 2023/0399383 A1Published application
Anti-rsv monoclonal antibody formulation
AssigneeMedImmune, LLC
InventorsBrian LOBO, Deborah GOLDBERG
Life of this patent
Estimating the term…
Abstract
The present invention provides a formulation comprising: (i) an anti-RSV monoclonal antibody; and (ii) an ionic excipient; wherein the monoclonal antibody is present at a concentration of about 50 mg/ml or greater and the ionic excipient is present at a concentration of between 50 and 150 mM and the formulation has a pH of about 5.5 to about 7.5.
Claims28
1-36. (canceled)
A formulation comprising:
- an anti-Respiratory Syncytial Virus (RSV) monoclonal antibody that is present at a concentration of about 50 mg/ml or greater and comprises a light chain variable region having at least 90% identity to the amino acid sequence of SEQ ID NO:
- 9 and a heavy chain variable region having at least 90% identity to the amino acid sequence of SEQ ID NO:
- 10;
- wherein the formulation further comprises an ionic excipient present at a concentration of about 50 mM to about 150 mM and one or more buffers present at a concentration of about 10 mM to about 50 mM;
- and
- wherein the formulation has a pH of about 5.5 to about 7.5.
3 more elements
A formulation comprising:
- an anti-Respiratory Syncytial Virus (RSV) monoclonal antibody at 100 mg/mL, wherein the antibody comprises a light chain sequence of SEQ ID NO:
- 1 and a heavy chain sequence of SEQ ID NO:
- 2;
- 30 mM L-histidine/L-histidine hydrochloride;
- 80 mM L-arginine hydrochloride;
- 120 mM sucrose;
- and
- 0.02% (w/v) polysorbate 80,
- wherein the pharmaceutical formulation has a pH of 6.0.
6 more elements
Dependencies are inferred from the claim text.